Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Investing Activities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Cash from Investing Activities for 16 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 47.76% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.3 million, a 81.42% increase, with the full-year FY2024 number at -$19.9 million, changed N/A from a year prior.
  • Cash from Investing Activities was -$1.2 million for Q3 2025 at Gyre Therapeutics, up from -$3.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $52.9 million in Q2 2022 to a low of -$8.3 million in Q2 2024.
  • A 5-year average of $3.5 million and a median of -$1.2 million in 2025 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 393.94% in 2022, then crashed 405.43% in 2023.
  • Gyre Therapeutics' Cash from Investing Activities stood at $2.9 million in 2021, then plummeted by 98.22% to $51000.0 in 2022, then crashed by 10688.24% to -$5.4 million in 2023, then surged by 62.89% to -$2.0 million in 2024, then skyrocketed by 37.77% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cash from Investing Activities are -$1.2 million (Q3 2025), -$3.0 million (Q2 2025), and $2.0 million (Q1 2025).